Showing 1891-1900 of 2038 results for "".
- Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strengthhttps://modernod.com/news/alcon-announces-fda-approval-of-the-otc-switch-of-pataday-once-daily-relief-extra-strength/2478016/Alcon announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, has been approved by the FDA for sale over-the-counter (OTC) in the United States. Pataday Once Daily Relief Extra Strength is the first and only once
- Biogen Boosts Gene Therapy Strategy With Harvard Pact Focused on Inherited Eye Diseasehttps://modernod.com/news/biogen-boosts-gene-therapy-strategy-with-harvard-pact-focused-on-inherited-eye-disease/2477996/Mutations in more than 270 genes have been implicated in inherited eye diseases like retinitis pigmentosa. Now, Biogen has formed a research pact with Harvard’s Massachusetts Eye and Ear that’s aimed at developing a gene therapy to help some patients with these blinding diseases, according to a F
- New $1-Billion Fund Aims to Rescue “Collapsing” Antibiotic Pipelinehttps://modernod.com/news/new-1-billion-fund-aims-to-rescue-collapsing-antibiotic-pipeline/2477997/More than 20 biopharmaceutical companies on Thursday joined forces to invest nearly $1 billion in a new fund aimed at supporting the development of antibiotics to address the rapid rise of antimicrobial resistance (AMR). The AMR Action Fund, spearheaded by the International Federation of Ph
- Accelmed Partners Completes Acquisition of TearLabhttps://modernod.com/news/accelmed-partners-completes-acquisition-of-tearlab/2477991/Private equity firm Accelmed Partners II (AP-II) completed its $25 million acquisition of dry eye device maker TearLab. As a newly formed private company, TearLab is now positioned to pursue further development of its next-generation Discovery platform and seek out targeted acquisition opp
- CooperVision Encourages Free Registration for Focus on Eye Health National Summithttps://modernod.com/news/coopervision-encourages-free-registration-for-focus-on-eye-health-national-summit/2477992/CooperVision is encouraging the optometry, ophthalmology, vision science and public health communities to participate in the 9th annual “Focus on Eye Health National Summit,” presented by Prevent Blindness on Wednesday, July 15. The summit’s online format and no-cost
- Oertli Instrumente Names New Director of the Boardhttps://modernod.com/news/oertli-instrumente-names-new-director-of-the-board/2477983/Andreas Bosshard, co-owner and former managing director of Oertli Instrumente AG, handed over the chairmanship of the board to Andreas Schmidheini. The reorganization became effective January 1, 2020. In 1988, Mr. Bosshard joined Oertli Instrumente AG and took over as managing director in
- Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenavahttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-for-norse-2-study-of-lytenava/2477982/Outlook Therapeutics announced the completion of patient enrollment in its NORSE 2 clinical trial for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications. “We are extremely grateful to the patients and medical staff
- Envision Conference Goes Virtual This Augusthttps://modernod.com/news/envision-conference-goes-virtual-this-august/2477945/Envision has announced that it is shifting the format for Envision Conference East to a live-stream webinar occurring August 14-15, 2020. In addition to creating a safer environment in the midst of the COVID-19 crisis, the virtual format will facilitate participation in
- Sanofi Sees Potential Approval of COVID-19 Vaccine in First Half of 2021https://modernod.com/news/sanofi-sees-potential-approval-of-covid-19-vaccine-in-first-half-of-2021/2477923/Sanofi said Tuesday that it expects potential approval of a COVID-19 vaccine being jointly developed with GlaxoSmithKline in the first half of next year, brought forward from an earlier estimate of the second half of 2021. A phase 1/2 study of the recombinant protein-based vaccine approach, whic
- Gilead Looking to Test Easier-To-Use, Inhaled Version of Remdesivirhttps://modernod.com/news/gilead-to-begin-human-trials-for-the-inhaled-version-of-coronavirus-drug-remdesivir/2477919/Gilead Sciences said Monday that it hopes to begin clinical trials this summer evaluating an inhaled formulation of remdesivir, administered via a nebuliser, to patients with COVID-19. The experimental antiviral, which the FDA authorized for emergency use in early May, is currently given intraven